J. McSurdy-Freed

发表

Synthesis and structure-activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors.

J. F. Mack, J. Luengo, Ramona N Plant, 2012, Bioorganic & medicinal chemistry letters.

Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.

B. Smith, K. Ward, J. Kehler, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Differences in Effects on Myocardium and Mitochondria by Angiogenic Inhibitors Suggest Separate Mechanisms of Cardiotoxicity

R. Coatney, C. Davis, Kendall S. Frazier, 2010, Toxicologic pathology.

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase

K. Ward, B. R. Smith, J. Mumaw, 2001, Xenobiotica; the fate of foreign compounds in biological systems.

SB-239063, a Potent and Selective Inhibitor of P38 Map Kinase: Preclinical Pharmacokinetics and Species-Specific Reversible Isomerization

B. Smith, K. Ward, L. M. Azzarano, 2001, Pharmaceutical Research.

Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.

J. F. Mack, J. Luengo, Ramona N Plant, 2012, ACS medicinal chemistry letters.

SB-242235, a selective inhibitor of p38 mitogenactivated protein kinase. I: Preclinical pharmacokinetics

K. Ward, B. R. Smith, L. M. Azzarano, 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors.

J. Luengo, Ramona N Plant, K. Erhard, 2013, ACS medicinal chemistry letters.

Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors.

J. Luengo, Ramona N Plant, K. Erhard, 2012, Bioorganic & medicinal chemistry letters.

Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells

Jennifer B Dennison, G. Mills, J. Briand, 2013, Cancer & Metabolism.

Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells

Jennifer B Dennison, G. Mills, J. Briand, 2013, Cancer & metabolism.

Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor.

C. Davis, S. Ferrer, D. Gargallo, 2006, Journal of pharmaceutical sciences.